HLS Therapeutics Inc.
HLS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.93% | -42.94% | 38.21% | -46.74% | 37.59% |
| Total Depreciation and Amortization | -0.87% | 0.51% | 2.29% | -1.36% | -1.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.43% | 180.62% | -13.73% | -16.15% | -4.31% |
| Change in Net Operating Assets | 403.11% | -157.55% | -34.12% | 39,080.00% | -350.00% |
| Cash from Operations | 162.80% | -46.22% | 29.95% | 10.55% | 113.52% |
| Capital Expenditure | 48.44% | 26.44% | -314.29% | -61.54% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -31.63% | 78.50% | -- | -- | -- |
| Cash from Investing | -13.26% | 74.33% | -5,076.19% | -61.54% | 99.13% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 91.15% | -579.76% | -178.18% | -16.92% | 82.42% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 99.11% | 6.00% | -373.30% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 86.23% | -- | -- | -- | -- |
| Cash from Financing | -55.87% | 63.61% | -188.66% | -23.55% | 82.42% |
| Foreign Exchange rate Adjustments | 195.31% | -134.88% | 948.57% | 105.63% | -618.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 168.73% | 75.36% | -2,107.55% | 430.95% | 99.44% |